March 2nd, 2023
AAIDA hosted Simu Thomas, Ph.D, of Alexion Pharmaceuticals and Shelby Harrington, RN, of Avalere, for our 2nd educational webinar during Rare Disease Week, 2023.
Simu and Shelby will discuss the following:
- Advancements in healthcare systems with patient-centric ways to evaluate health technology and outcomes
- New approaches to address total indirect burden of a disease for patients, such as productivity loss, family and caregiver impacts, and the severity of disease states
- Discuss new findings from a report with patient-focused methods to determine the value of health technology for rare disease patients
Shelby Harrington, RN, is Principal at Avalere who began her career at Carolinas HealthCare System (now Atrium Health) as a staff nurse in orthopedics and trauma care in Charlotte, N.C. Shelby now supports clients in navigating the transition to value-based care with a focus on clinical quality, strategy, and digital transformation. Recently, Shelby has helped life sciences manufacturers develop value-based care strategies to characterize patient-centric outcomes linked with their products (e.g., improved mental health, relationships, and employment, and ability to work and parent), particularly for rare and chronic diseases. Shelby has also served as senior product director for quality and regulatory technology at Premier, Inc., overseeing hospital regulatory products, provider registries and value analytics products. Shelby holds a bachelor’s degree in public policy analysis from the University of North Carolina at Chapel Hill and bachelor’s and master’s degrees in nursing from Virginia Commonwealth University.
Simu Thomas, Ph.D., is Vice President of Global Head Health Economics & Outcomes Research for Alexion Pharmaceuticals, AstraZeneca Rare Disease. Prior to joining Alexion, Simu was the Global Head of Value & Access for Rare Diseases at Novartis, Global Head for the Cell & Gene Therapy Unit, where he developed the Value Access strategy for rare diseases and the first CART therapy approved in the world. He was also the founding architect of the IMI HARMONY data initiative. Simu ran the Economic Modeling organization at Novartis and has authored more than 35 manuscripts and 75 congress presentations and co-authored book chapters in the field of Health Economics. Simu holds a PhD in Pharmaceutical Economics from the University of Maryland and MS in Pharmacy Administration from the University of Toledo and Pharmacy degrees. Simu also serves as Adjunct Assistant Professor at University of Maryland and Rutgers University of New Jersey.
Following their presentation Shelby and Simu will conduct a live 15 minute Q & A session with attendees. This webinar will be recorded live and made available on the AAIDA website and YouTube channel in the following days.
This presentation was sponsored in partnership with Alexion Pharmaceuticals.